Holen Sie sich die Stockscreener-App
11.47
0.79%
0.0746
Schlusskurs vom Vortag:
$11.40
Offen:
$11.28
24-Stunden-Volumen:
852.10K
Relative Volume:
0.25
Marktkapitalisierung:
$813.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-6.1035
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
+21.85%
1M Leistung:
+74.36%
6M Leistung:
+204.77%
1J Leistung:
+0.97%
1-Tages-Spanne:
$11.13
$11.65
1-Wochen-Bereich:
$9.31
$11.65
52-Wochen-Spanne:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Vergleichen Sie OMER mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.48 | 808.27M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
Omeros Corporation's (NASDAQ:OMER) Shift From Loss To Profit - Yahoo Finance
Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval? - Insider Monkey
Omeros Completes Major Asset Deal with Novo Nordisk - MSN
Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? - MSN
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
Omeros (NASDAQ:OMER) Stock Price Up 8.2%Still a Buy? - MarketBeat
Can Omeros Corporation stock outperform in 2025 bull marketJuly 2025 Update & Short-Term High Return Ideas - Newser
Omeros Corporation's (NASDAQ:OMER) Surges Amid Clinical Advancements - Kalkine Media
Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital - MarketBeat
Aug Sentiment: Is Omeros Corporation stock attractive for income investorsMarket Volume Report & Smart Allocation Stock Tips - BỘ NỘI VỤ
How Omeros Corporation stock performs in weak economyChart Signals & Entry Point Confirmation Alerts - Newser
Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Cap - GuruFocus
Omeros Shares Jump After Finalizing $340 Million Novo Nordisk Deal - MSN
Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus
Omeros Closes Asset Purchase, Licensing Deal With Novo Nordisk for Zaltenibart - MarketScreener
Omeros, Novo Nordisk Close Up to $2.1B Deal for Rare Disease Drug Zaltenibart, NOVO Stock - Somos Hermanos -
Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - MSN
Omeros receives $240 million upfront from Novo Nordisk deal By Investing.com - Investing.com Canada
Omeros receives $240 million upfront from Novo Nordisk deal - Investing.com
Omeros stock surges after closing $340 million deal with Novo Nordisk - Investing.com Australia
Omeros stock surges after closing $340 million deal with Novo Nordisk By Investing.com - Investing.com South Africa
Omeros closes asset purchase and license deal with Novo Nordisk for MASP-3 inhibitor zaltenibart - marketscreener.com
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Yahoo Finance
Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - simplywall.st
What catalysts could drive Omeros Corporation stock higher2025 Short Interest & Weekly Top Stock Performers List - moha.gov.vn
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha
What technical signals suggest for Omeros Corporation stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Omeros Corporation Stock Analysis and ForecastInsider Selling Patterns & Free Stock Trading Workshops - earlytimes.in
Is Omeros Corporation stock cheap compared to fundamentalsIPO Watch & Technical Entry and Exit Tips - newser.com
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Omeros (NASDAQ:OMER) Shares Down 5.6%Should You Sell? - MarketBeat
Here's Why Shares in Theravance Biopharma Exploded Today - AOL.com
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com
How strong is Omeros Corporation stock revenue growthBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Omeros (NASDAQ:OMER) Stock Price Up 8.1%Time to Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Q3 2025 Earnings Call Transcript - Insider Monkey
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying - AOL.com
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch - AOL.com
Omeros Corporation’s Earnings Call Highlights Strategic Moves - TipRanks
test-commerce-234 - AOL.com
Omeros (OMER) Q3 2025 Earnings Call Transcript - The Globe and Mail
Published on: 2025-11-17 02:29:02 - newser.com
Transcript : Omeros Corporation, Q3 2025 Earnings Call, Nov 13, 2025 - marketscreener.com
Omeros Corporation stock outlook for YEARJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):